Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007515 | 1.00 | ALOX15 (0.38) | ALOX15CA1CA2CA7CA9 | |
| SCHEMBL3286596 | 1.00 | ALOX15 (0.38) | ALOX15CA1CA2CA7CA9 | |
| SCHEMBL29342865 | 0.97 | ALOX15 (0.36) | ALOX15CA1CA2CA7CA9 | |
| SCHEMBL29343105 | 0.97 | ALOX15 (0.36) | ALOX15CA1CA2CA7CA9 | |
| SCHEMBL24933005 | 0.88 | CA1 (0.44) | ALOX15CA1CA2CA7CA9 | |
| SCHEMBL30876749 | 0.86 | TDP1 (0.39) | ALOX15CA1CA2CA7CA9 | |
| SCHEMBL11195121 | 0.85 | ALOX15 (0.38) | ALOX15CA1CA2CA7CA9 | |
| SCHEMBL8904530 | 0.84 | CA1 (0.51) | CA1CA2CA7CA9TSHR | |
| SCHEMBL19043237 | 0.84 | TSHR (0.45) | CA1CA2CA7CA9TSHR | |
| SCHEMBL828589 | 0.84 | CA1 (0.51) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076520-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20100280282-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7709464-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090035358-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2009-02-05 | — | — | US | disclosed |
| US-7351428-B2 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20040213836-A1 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2004-10-28 | — | — | US | disclosed |
| US-20030053978-A1 | Phosphatidyl oligoglycerols | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2003-03-20 | — | — | US | disclosed |
| US-20020090383-A1 | Compounds which increase the survival duration of liposomes | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2002-07-11 | — | — | US | disclosed |
| US-6413543-B1 | DRUG DELIVERY | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040213836-A1 | Phosphatidyl oligoglycerols | PHOSPHO1, SGMS1, SGMS2 | ALOX15 423/4885CA1 3928/4885CA2 4024/4885 |
| US-20030053978-A1 | Phosphatidyl oligoglycerols | PHOSPHO1, SGMS1, SGMS2 | ALOX15 411/4885CA1 4298/4885CA2 3994/4885 |
| US-20020090383-A1 | Compounds which increase the survival duration of liposomes | VEGFA, MCL1, LIPA | ALOX15 589/4885CA1 2013/4885CA2 3532/4885 |
| US-20100280282-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | PHOSPHO1, SGMS2, LIPG | ALOX15 508/4885CA1 4665/4885CA2 4175/4885 |
| US-20090035358-A1 | PHOSPHATIDYL OLIGOGLYCEROLS | PHOSPHO1, SGMS2, LIPG | ALOX15 508/4885CA1 4665/4885CA2 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.